[ad_1]
The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out a key provision that would have expanded coverage for weight-loss drugs. In response, Eli Lilly (LLY) stock skidded.
As outlined by the Centers for Medicare and Medicaid Services, Medicare Advantage will not pay for the cost of anti-obesity medications. The Biden administration previously attempted to have Medicare Part D and Medicaid cover weight-loss drugs. The move would have massively expanded access, likely even helping push commercial insurance coverage.
↑
X
The Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy?
New Health Secretary Robert F. Kennedy Jr. has been skeptical of weight-loss drugs, instead preferring nutrition and exercise to help control obesity and type 2 diabetes. But proponents say covering anti-obesity drugs could help curb future — and rising — costs associated with chronic illnesses.
The news is a blow for Eli Lilly and Novo Nordisk (NVO), which sell blockbuster weight-loss drugs Zepbound and Wegovy, respectively. Eli Lilly stock toppled 32.7% to 718.50, adding to a 6.4% loss during the regular session. Novo Nordisk shares slipped 1.2% to 61.80, following a 6.7% regular-session dive.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
YOU MAY ALSO LIKE:
Sarepta Dives On ‘Another Unfortunate Development’ For Its Gene Therapy
Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch
MarketSurge: Research, Charts, Data And Coaching All In One Place
When To Sell Growth Stocks: Don’t Freeze If A Double-Digit Gain Shrinks Fast
[ad_2]
Source link